China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
